Global Animal Antibiotics and Antimicrobials Market

1 INTRODUCTION OF GLOBAL ANIMAL ANTIBIOTICS AND ANTIMICROBIALSMARKET
1.1 Overview of the Market
1.2 Scope of Report
1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET INTELLIGENCE
3.1 Data Mining
3.2 Validation
3.3 Primary Interviews
3.4 List of Data Sources

4 GLOBAL ANIMAL ANTIBIOTICS AND ANTIMICROBIALSMARKETOUTLOOK
4.1 Overview
4.2 Market Dynamics
4.2.1 Drivers
4.2.2 Restraints
4.2.3 Opportunities
4.3 Porters Five Force Model
4.4 Value Chain Analysis
4.5 Regulatory Framework

5 GLOBAL ANIMAL ANTIBIOTICS AND ANTIMICROBIALS MARKET, BY MODE OF DELIVERY:
5.1 Overview
5.2 Premixes
5.3 Oral Powders
5.4 Oral Solutions
5.5 Injections
5.6 Other Modes of Delivery

6 GLOBAL ANIMAL ANTIBIOTICS AND ANTIMICROBIALS MARKET, BY PRODUCT:
6.1 Overview
6.2 Tetracyclines
6.3 Penicillins
6.4 Sulfonamides
6.5 Macrolides
6.6 Aminoglycosides
6.7 Lincosamides
6.8 Fluoroquinolones
6.9 Cephalosporins
6.10 Other Antimicrobials and Antibiotics

7 GLOBAL ANIMAL ANTIBIOTICS AND ANTIMICROBIALS MARKET, BY TYPE OF ANIMAL:
7.1 Overview
7.2 Food Producing
7.2.1 Cattle
7.2.2 Pigs
7.2.3 Poultry
7.2.4 Sheep and Goats
7.2.5 Other Food-Producing Animals
7.3 Companion
7.3.1 Dogs
7.3.2 Cats
7.3.3 Horses
7.3.4 Other Companion Animals

8 GLOBAL ANIMAL ANTIBIOTICS AND ANTIMICROBIALSMARKET, BY GEOGRAPHY
8.1 Overview
8.2 North AmericaRegional Market Estimates and Forecasts, 2012 - 2025
8.2.1 U.S.
8.2.2 Canada
8.2.3 Mexico
8.3 EuropeRegional Market Estimates and Forecasts, 2012 - 2025
8.3.1 Germany
8.3.2 U.K.
8.3.3 France
8.3.4 Rest of Europe
8.4 Asia PacificRegional Market Estimates and Forecasts, 2012 - 2025
8.4.1 China
8.4.2 Japan
8.4.3 India
8.4.4 Rest of Asia Pacific
8.5 Latin AmericaRegional Market Estimates and Forecasts, 2012 - 2025
8.5.1 Brazil
8.5.2 Argentina
8.6 Rest of the WorldRegional Market Estimates and Forecasts, 2012 - 2025

9 GLOBAL ANIMAL ANTIBIOTICS AND ANTIMICROBIALSMARKETCOMPETITIVE LANDSCAPE
9.1 Overview
9.2 Company Market Share
9.3 Vendor Landscape
9.4 Key Development Strategies

10 COMPANY PROFILES
10.1 Zoetis, Inc.
10.1.1 Overview
10.1.2 Financial Performance
10.1.3 Product Outlook
10.1.4 Key Developments

10.2 BoehringerIngelheim GmbH
10.2.1 Overview
10.2.2 Financial Performance
10.2.3 Product Outlook
10.2.4 Key Developments

10.3 Eli Lilly and Company
10.3.1 Overview
10.3.2 Financial Performance
10.3.3 Product Outlook
10.3.4 Key Developments

10.4 Merck & Co., Inc.
10.4.1 Overview
10.4.2 Financial Performance
10.4.3 Product Outlook
10.4.4 Key Developments

10.5 Bayer AG
10.5.1 Overview
10.5.2 Financial Performance
10.5.3 Product Outlook
10.5.4 Key Developments

10.6 Sanofi
10.6.1 Overview
10.6.2 Financial Performance
10.6.3 Product Outlook
10.6.4 Key Developments

10.7 CevaSanteAnimale
10.7.1 Overview
10.7.2 Financial Performance
10.7.3 Product Outlook
10.7.4 Key Developments

10.8 Virbac
10.8.1 Overview
10.8.2 Financial Performance
10.8.3 Product Outlook
10.8.4 Key Developments

10.9 Vetoquinol S.A.
10.9.1 Overview
10.9.2 Financial Performance
10.9.3 Product Outlook
10.9.4 Key Development

10.10 Dechra Pharmaceuticals PLC
10.10.1 Overview
10.10.2 Financial Performance
10.10.3 Product Outlook
10.10.4 Key Development

11 Appendix
11.1 Related Reports